Vascular disease: obesity and excess weight as modulators of risk

References

• World Health Organization Fact Sheet. No. 317 WHO, Geneva, Switzerland (2009).
   Google Scholar
• Yusuf S, Reddy S, Ounpuu S et al. Global burden of cardiovascular diseases. Part 11, varations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circ.104, 285–264 (2001).
   Google Scholar
• Rao GHR, Kakkar VV. Coronary Artery Disease in South Asians: Epidemiology, Risk Factors and Prevention. JP Medical Publishers, New Delhi, India (2001).
   Google Scholar
• Rao GHR, Thanikachalam S. Coronary Artery Disease: Pathophysiology, Risk Promoters and Prevention. JP Medical Publishers, New Delhi, India (2005).
   Google Scholar
• Kanjilal S, Rao VS, Mukherjee M et al. Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vasc. Health Risk Manag.4, 199–211 (2008).
   PubMedGoogle Scholar
• Johnson KM, Dowe DA. The detection of any coronary calcium outperforms Framingham risk score as a first step in screening coronary atherosclerosis. Am. J. Roentgenol.194, 1235–1243 (2010).
   PubMed Web of Science ®Google Scholar
• GarcÍa-GarcÍa HI, Gonzalo N, Granada JF et al. Diagnosis and treatment of cornary vilnerable plaques. Exp. Rev. Cardiovas. Ther.6, 209–222 (2008).
   PubMedGoogle Scholar
• Landry A, Spence DJ, Fester A. Measurement of carotid plaque volume by 3-dimensional ultrasound. Stroke35, 864–869 (2004).
   PubMed Web of Science ®Google Scholar
• Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am. J. Cardiol.16, 101(12A) 3F–10F (2008).
   Google Scholar
• Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk? Prog. Cardiovasc. Nurs.24, 181–189 (2009).
   PubMedGoogle Scholar
• Shishehbor MH, Zhang R, Median H et al. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Rad. Biol. Med.41, 1678–1683 (2006).
   PubMed Web of Science ®Google Scholar
• Febbraio M, Silverstein RL. CD36, implications in cardiovascular disease. Int. J. Biochem. Cell Biol.39, 2012–2030 (2007).
   PubMed Web of Science ®Google Scholar
• Barker DJP. Fetal Origins on Adult Disease. BMJ Books London, UK (1992).
   Google Scholar
• Barker DJP. Outcome of low birthweight. Horm. Res.42, 223–230 (1994).
   PubMedGoogle Scholar
• WHO: maternal anthropometry and pregnancy outcomes: a WHO collaborative study. Bull. World Health Organ.73, (Suppl. 1–6) (1995).
   Google Scholar
• Yajnik CS. Interactions of perturbation in intrauterine growth and during child hood on the risk of adult onset disease. Proc. Nutr. Soc.59, 257–265 (2000).
   PubMed Web of Science ®Google Scholar
• Yajnik CS. Fetal origins of health and disease, commentary: fetal origins of cardiovascular risk-nutritional and non-nutritional. Ind. J. Epi.30, 57–59 (2001).
   PubMedGoogle Scholar
• Veena SR, Geetha S, Leary SD et al. Relationship of maternal and paternal birthweight to features of the metabolic syndrome in the adult offspring; an intergenerational study in South India. Diabetologia50, 43–54 (2007).
   PubMedGoogle Scholar
• Robinson R. The fetal origins of adult disease. No longer just a hypothesis and may be critically important in South Asia. BMJ322, 375–376 (2001).
   PubMed Web of Science ®Google Scholar
• Scrimshaw NS. The relation between fetal malnutrition and chronic diseases later in life: good nutrition and lifestyle matter from womb to tomb. BMJ315, 825–826 (1997).
   PubMed Web of Science ®Google Scholar
• Mohan V, Rao GHR. Type-2 diabetes: Epidemiology, Risk Factors and Prevention. JP Medical Publishers, New Delhi, India (2007).
   Google Scholar
• Despres J, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Art. Thromb. Vasc. Biol.28, 1039–1049 (2008).
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Art. Thromb. Vasc. Biol.27, 996–1003 (2007).
   PubMed Web of Science ®Google Scholar
• Fryar CD, Hirsch R, Eberhardt MS et al. Hypertension, high serum total cholesterol, and diabetes: racial and ethnic prevalence differences in U.S. adults, 1999–2006. NCHS Data Brief36, 1–8 (2010).
   PubMedGoogle Scholar
• Marinou K, Tousoulis D, Antonopoulos AS et al. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int. J. Cardiol.138, 3–8 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kompoti M. Obesity and infection. Lancet Infect. Dis.6, 438–446 (2006).
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Stechouwer JJ, Emeis SW et al. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Art. Thromb. Vasc. Biol.19, 972–978 (1999).
   PubMed Web of Science ®Google Scholar
• Gustafson B. Adipose tissue, inflammation and atherosclerosis. J. Art. Thromb.17, 332–341 (2010).
   PubMed Web of Science ®Google Scholar
• Ohmura K, Ishimori N, Ohmura Y et al. Natural killer T cells are involved in adipose tissue inflammation and glucose intolerance in diet-induced obese mice. Art. Thromb. Vasc. Biol.30, 193099 (2010).
   Google Scholar
• Wu H, Perrad XD, Wang Q et al. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Art. Thromb. Vasc. Biol.30, 186–192 (2010).
   PubMed Web of Science ®Google Scholar
• Heida NM, Leifheit-Nestler M, Schroeter M et al. Leptin enhances the potency of Circulating angiogenic cells via SRc kinase and integrinv5, implications for angiogensis in human obesity. Art. Thromb. Vasc. Biol.30, 200–206 (2010).
   PubMedGoogle Scholar
• Xuan-Mai, Nguyen JL, Smith BR et al. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J. Gastrointest. Surg.13(7), 1205–1212 (2009).
   PubMedGoogle Scholar
• Van der Zwan LP, Scheffler PG Dekker JM et al. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension55(6), 1366–1372 (2010).
   PubMedGoogle Scholar
• Libby P, Okamoto Y, Rocha VZ et al. Inflammation and atherosclerosis. Circ. J.74, 213–220 (2010).
   PubMed Web of Science ®Google Scholar
• Gerrard JM, Stuart MJ, Rao GHR. Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J. Lab. Clin. Med.95, 95058 (1980).
   Google Scholar
• Souza MG, Rivera IR, Silva MA et al. Relationship of obesity with high blood pressure in children and adolescents. Arq. Bras. Cardiol.94(6), 714–719 (2010).
   PubMedGoogle Scholar
• Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogenesis. An anthropological journey. Am. J. Path.173, 1253–1264 (2008).
   PubMed Web of Science ®Google Scholar
• Deeb RS, Lamon BD, Hajjar DP. Silent partner in blood vessel homeostasis pervasive role of nitric oxide in vascular disease. Curr. Hpertens. Rev.5, 273–282 (2009).
   PubMedGoogle Scholar
• Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Vert. K. Acad. Genneskd. Belg.70(3), 193–219 (2008).
   PubMedGoogle Scholar
• Aschner P. Metabolic syndrome as a risk for factor for diabetes. Expert Rev. Cardiovasc. Ther.8(3), 407–412 (2010).
   PubMedGoogle Scholar
• Dietz WH. Overweight in childhood and adolescence. N. Engl. J. Med.350, 855–857 (2004).
   PubMed Web of Science ®Google Scholar
• Isgnaitis E, Lustig RH. Fast food, central nervous system insulin resistance and obesity. Art. Throm. Vasc. Biol.25, 2451–2462 (2005).
   PubMedGoogle Scholar
• Camhi SM, Kuo J, Young DR. Identifying adolescent metabolic syndrome using body mass index and waist circumference. Prev. Chronic. Dis.5(4), A115 (2008).
   Google Scholar
• Short KR, Blackett PR, Gardner AW et al. Vascular health in children and adolescent: effect of obesity and diabetes. Vasc. Health Risk Manag.5, 973–990 (2009).
   PubMedGoogle Scholar
• Liu LL, Lawrence JM, Davis C et al. Prevalence of obesity in youth with diabetes in USA: the SERACH for diabetes in youth study. Pediatr. Diabetes11(1), 4–11 (2011).
   Google Scholar
• Wild S, Roglic G, Green A et al. Global prevalence of diabetes; estimates for the year (2000) and projections for (2030). Diabetes Care27, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Vijay V et al. Temporal changes in prevalence of Type-2 diabetes and impaired glucose tolerance in urban southern India. Diabetes Res. Clin. Pract.58, 55–60 (2002).
   PubMedGoogle Scholar
• Mohan V, Deepa M, Deepa R et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in the urban south India-the Chennai Urban Rural Epidemiology Study (CURES-17) Diabetologia49, 1175–1178 (2006).
   PubMed Web of Science ®Google Scholar
• Ramachandra A, Snehalatha C, Kapur A et al. For The Diabetes Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired glucose tolerance in India. National Urban Diabetes Survey. Diabetologia44, 1094–1101 (2001).
   PubMedGoogle Scholar
• Nathan DM, Zinman B, Cleary PA et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of Type 1 diabetes mellitus after 30 years duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch. Intern. Med.169, 1307–1316 (2009).
   PubMed Web of Science ®Google Scholar
• Clark CM. How should we respond to the worldwide diabetes epidemic? Diabetes Care21, 475–476 (1998).
   PubMedGoogle Scholar
• Mathew M, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiov. Diab.9, 1–9 (2010).
   PubMedGoogle Scholar
• Linjen HR. Role of fibrinlysis in obesity and thrombosis. Thromb. Res.123, S46–S49 (2009).
   Google Scholar
• Schneider DJ, Hardison RH, Lopes N et al. Association between increased platelet P-selectin expression and obesity in patients with Type 2 diabetes. A BRI 2D (bypass angioplasty revascularization investigation 2 diabetes) substudy. Diabetes Care32, 944–949 (2009).
   PubMedGoogle Scholar
• Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity. Studies of PAI-1. Art. Thromb. Vasc. Biol.18, 1–6 (1998).
   PubMedGoogle Scholar
• Darvall KA, Sam RC, Silverman SH et al. Obesity and thrombosis. Eur. J. Vasc. Endovasc. Surg.33, 223–233 (2006).
   PubMedGoogle Scholar
• Stein PD, Beeman A, Olson E et al. Obesity as a risk factor in venous thromboembolism. Am. J. Med.118, 978–980 (2005).
   PubMed Web of Science ®Google Scholar
• Nagai N, Hoylaerts MF, Linjen HR et al. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb. Res.122, 549–555 (2008).
   PubMedGoogle Scholar
• Eichinger S, Hron G, Bialonczyk C et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Int. Med.168, 1678–1683 (2008).
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Olson RE et al. Obesity as a risk factor in venous thromboembolism. Am. J. Med.118, 978–980 (2005).
   PubMed Web of Science ®Google Scholar
• Stein PD, Goldman J. Obesity and thromboembolic disease. Clin. Chest. Med.30, 489–493 (2009).
   PubMed Web of Science ®Google Scholar
• Abu JB, Lu J, Mooradian AD et al. Relationship of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity18, 1046–1054 (2010).
   PubMedGoogle Scholar
• Puska P. Cornary artery disease and stroke in developing countries: time to act. Int. J. Epi. Assoc.30, 1493–1494 (2001).
   PubMedGoogle Scholar
• Calza S, Decarli A, Ferraroni M et al. Obesity and prevalence of chronic diseases in the 1999–2000 Italian National Survey. BMC Pubic Health8, 140–149 (2008).
   PubMedGoogle Scholar
• Bigornia SJ, Mott MM, Hess DT et al. Long-term successful weight loss improves vascular endothelial function in severely obese individuals. Obesity18, 754–759 (2010).
   PubMedGoogle Scholar
• Lee YH, Jeong HS, Kim NS et al. The effect of an exercise program on anthropometric metabolic and cardiovascular parameters in obese children. Korean Circ.40, 179–184 (2010).
   PubMedGoogle Scholar
• Padwal R, Li SK, Lau DC et al. Long-term pharmacotherapy for overweight and obesity: a systemic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord.27, 1437–1446 (2003).
   PubMed Web of Science ®Google Scholar
• Leung WY, Thomas GN, Chan JC et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin. Ther.25, 58–80 (2003).
   PubMed Web of Science ®Google Scholar
• Loannides-Demos L, Proietto J, McNeil JJ et al. Pharmacotherapy for obesity. Drugs65, 1391–1418 (2005).
   PubMedGoogle Scholar
• Antiplatelet Trialists’ Collaboration. The aspirin papers. Brit. J. Med.308, 71–72, 81–106 (1994).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diab. Care32, 531–540 (2009).
   PubMed Web of Science ®Google Scholar
• Jalil AN. Hypercoagulation in diabetes mellitus. Southeast Asian J. Trop. Med. Public Health.1, 263–266 (1993).
   Google Scholar
• Carr ME. Diabetes mellitus: a hypercoagulable state. J. Diab. Complications15, 44–54 (2001).
   PubMed Web of Science ®Google Scholar
• Rolka DB, Fagot-Campagna A Narayan KM et al. Aspirin use among adults with diabetes. Estimates from the Third National Health and Nutrition Examination Survey (NHANES III). Diabt. Care.24, 197–201 (2001).
   PubMed Web of Science ®Google Scholar
• Miller SR. Littenberg B, MacLean CD et al. Prevalence of antiplatelet therapy in patients with diabetes. Cardiovasc. Diabet.4, 18 (2005).
   PubMedGoogle Scholar
• Steering Committee of the Physicians’ Health Study Group. Final report on the aspirin component of the ongoing physicians’ health study. N. Engl. J. Med.321, 129–135 (1989).
   PubMed Web of Science ®Google Scholar
• ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA268, 1292–1300 (1992).
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T et al. Low dose aspirin for the prevention of atherosclerotic events in patients with Type 2 diabetes: a randomized controlled clinical trial. JAMA300, 2134–2141 (2008).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Aspirin therapy in diabetes: position statement. Clin. Diab.21, 45–46 (1998).
   Google Scholar
• Belch H, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ337, 1840 (2008).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel in patients with diabetes mellitus. Am. J. Cardiol.90, 625–628 (2002).
   PubMed Web of Science ®Google Scholar
• Chen K, Rha S, Li Y et al. Triple versus dual Antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Circulation119, 3207–3214 (2009).
   PubMed Web of Science ®Google Scholar
• Duggan ST, Keating GM. Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary interventions. Drugs69, 1707–1726 (2009).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar